Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grass MATA MPL in seasonal allergic rhinoconjunctivitis
NCT03931993Phase 1Completed
- Sponsor
- Allergy Therapeutics PLC
- Start
- Jan 2017
- Primary completion
- Apr 2017
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in Seasonal Allergic Rhinoconjunctivitis (SAR) comparing Placebo with Grass MATA MPL 35600 SU (2 arms). Primary endpoints: Adverse Events, Adverse Reaction Complexes and 9 more. Started Jan 2017; status: completed.
02
Drugs
Grass MATA MPL
03
Conditions
Seasonal Allergic Rhinoconjunctivitis (SAR)
Beyond the preview
Go deeper on NCT03931993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03931993.